BOSTON, Sept. 16 (Reuters) - Amgen Inc, the world’s biggest biotechnology company, said on Tuesday that its experimental osteoporosis drug denosumab reduced the risk of vertebral fractures in post-menopausal women by 68 percent compared with patients taking a placebo.